Cerino PVM

Language: Spanish
References: 17
Page: 80-82
PDF size: 101.03 Kb.

REFERENCES

1. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020; 133 (12): 1380-1390.e2.

2. Sabatino JJ Jr, Zamvil SS, Hauser SL. B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med. 2019; 9 (2): a032037.

3. Milo R. Therapies for multiple sclerosis targeting B cells. Croat Med J. 2019; 60 (2): 87-98.

4. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017; 376 (3): 221-234.

5. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017; 376 (3): 209-220.

6. Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021; 97 (16): e1546-e1559.

7. Aguilar-Juárez PA, Castillo-Lara RA, Ceballos-Godina M, Colorado-Ochoa HJ, Espinosa-Zacarías JP, Flores-Ramírez FG et al. Consenso para el diagnóstico y tratamiento de la esclerosis múltiple en pacientes del ISSSTE. Med Interna Méx. 2019; 35 (5): 732-771.

8. Bermel R, Hatung H, Brochet B et al. Low disease activity over 4 years of ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis: the phase 3b ENSEMBLE study. Presented at: 2023 AAN Annual Meeting; Boston, MA. Abstract 001928.

9. Weber MS, Kappos L, Hauser SL, Schneble HM, Wang Q, Giovannoni G. Delayed Signs of early disability progression after 8.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Presented at the 75th Annual Meeting of the American Academy of Neurology (AAN), April 22–27, 2023, Boston, MA, USA.

10. De Seze J, Hauser SL, Kappos L, Montalban X, Pozzilli C, Chognot C et al. Infusion-related reactions with ocrelizumab in phase III studies. EP1671. ECTRIMS. Paris, France: 2017; 199691.

11. Hauser S, Kappos L, Montalban X, Chin P, Green MC, Koendgen H et al. Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. P686. ECTRIMS. Paris, France. Oct 26, 2017; 200341.

12. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90 (17): 777-788.

13. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018; 24 (2): 96-120.

14. Bove R, Hellwig K, Pasquarelli N, Borriello F, Dobson R, Oreja-Guevara C et al. Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants. Mult Scler Relat Disord. 2022; 64: 103963.

15. Ocrevus: EPAR-product information. European Medicines Agency. 2017. Available in: http://www.ema.europa.eu/ema/

16. Stahnke AM, Holt KM. Ocrelizumab: a new b-cell therapy for relapsing remitting and primary progressive multiple sclerosis. Ann Pharmacother. 2018; 52 (5): 473-483.

17. Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020; 95 (14): e1999-e2008.